Posted by ACI Limited
The New England Journal of MedicineMolnupiravir is an orally
administered form of a potent ribonucleoside analog that inhibits the
replication of SARS-CoV-2. For nonhospitalized, unvaccinated adults with
mild-to-moderate COVID-19 and at least one risk factor for severe disease,
molnupiravir reduces the risk for hospitalization or death, accordi...
The U.S. Food and Drug
Administration approved the emergency use of the molnupiravir pill for the
treatment of mild-to-moderate coronavirus disease 2019 in nonhospitalized adult patients with positive
results of direct SARS-CoV-2 viral testing who are at high risk for progressing
to severe COVID-19, including hospitalization or death.Does molnu...
Journal of Neuro-Ophthalmology:
TAKE-HOME MESSAGE
This study reviewed
published literature regarding the ophthalmic manifestations of
COVID-19. Findings revealed that eye pain was caused by conjunctivitis,
episcleritis, scleritis, and optic neuritis, and headache was the result
of trigeminal nerve invasion and vascular effects. These mani...
INTRODUCTION
Coronavirus
disease 2019 (COVID-19) has increased the frequency of hand washing. There is
scarce evidence regarding the impact of different hand hygiene procedures on
skin barrier function in clinical practice.
For the
required proper hand hygiene procedures, currently there are several hand
hygiene products available, s...
Effectiveness
of Maternal Vaccination with mRNA COVID-19 Vaccine during Pregnancy against
COVID-19–Associated Hospitalization in Infants Aged
BMJ Open Diabetes Research & Care: BMJ Journal
Bangladeshi researchers identify
new pathological cause of diabetes.
The team
of researchers from multiple local and foreign universities, through a
five-year (2015-2020) study on 574 non-diabetic people aged between 30 and 60,
have discovered that deficiency of the Intestinal Alkaline Ph...
JAMA Internal Medicine
Ivermectin
treatment during early illness does not prevent progression to severe disease
for high-risk patients with mild-to-moderate COVID-19, according to a study
published online Feb. 18 in JAMA
Internal Medicine.
An in
vitro study demonstrated inhibitory effects of ivermectin against SARS-CoV-2.
Although s...
JAMA Network:
SARS-CoV-2 continues to infect more
than 22 million patients per week and globally causes more than 65 000 deaths
per week as of January 31, 2022.
Although aspirin has not been shown
to reduce major adverse cardiovascular or pulmonary events in symptomatic
outpatients with COVID-19, several observational studies have fou...
Coronavirus (COVID-19) Vaccine Update:
Take Home Message:
A single booster dose of the Pfizer
COVID-19 vaccine can be given to 5- to 11-year-olds to provide continued
protection against COVID-19., the U.S. Food and Drug Administration announced.
The third shot can be given at
least five months after healthy children complete the two...
European Heart Journal:
Worldwide, survivors of COVID-19
now exceed hundreds of millions, with some reporting incomplete recovery months
beyond the acute illness, a condition commonly referred to as long COVID.
Persistent symptoms of breathlessness, chest pain, fatigue, headaches, brain
fog, and palpitations are a constant reminder of th...
American Academy of Neurology (AAN) Journal:
Novel coronavirus disease
(COVID-19) has been suggested to not only affect health during the acute phase
of the SARS-CoV-2 infection, but some manifestations have been consistently
reported also after the recovery. Such phenomenon has been named “long-COVID”
or “post-acute COVID-19”.
These...
American Academy of Pediatric Journal:
TAKE-HOME MESSAGE
This retrospective cohort study
looked at the association between asthma and SARS-CoV-2 infection risk in
children aged 5 to 17 years. Children who had asthma were more likely to be
tested for SARS-CoV-2 infection than those without asthma.
However, the infection rates among...
